Sign in

You're signed outSign in or to get full access.

Peter K. Markell

Director at Huron Consulting Group
Board

About Peter K. Markell

Independent director of Huron Consulting Group Inc. since March 2022; age 69. Executive Vice President and CFO of Brown University Health (formerly Lifespan Health System) since 2023; previously EVP of Administration & Finance, CFO and Treasurer at Mass General Brigham (1999–2021), with prior roles including Audit Partner at Ernst & Young and Interim CFO of Massachusetts General Hospital. BS/BA in Accounting and Finance from Boston College; inactive CPA. Serves as Audit Committee chair and is designated an “audit committee financial expert.”

Past Roles

OrganizationRoleTenureCommittees/Impact
Brown University Health (f/k/a Lifespan Health System)Executive Vice President and CFO2023–presentFinance leadership; proximity to Huron’s Boston Innosight team cited as beneficial
Mass General BrighamEVP Administration & Finance, CFO & Treasurer1999–2021Oversight of ~$14B operations and ~$21B assets; led corporate finance, research mgmt, IS, real estate, treasury, HR
Ernst & Young LLPAudit PartnerPrior to 1999Big Four audit experience
Massachusetts General HospitalInterim CFOPrior to 1999Hospital finance leadership

External Roles

OrganizationRoleTenureCommittees/Impact
Eastern BankDirector; Chair of Audit Committee; member of Compensation, Risk Management, and Nominating & Corporate GovernanceSince 2006Audit chair; multiple governance committees
Boston CollegeBoard of Trustees; Former ChairpersonNot specifiedHigher education governance
CodaMetrixDirector; Audit Committee memberNot specifiedHealth data/technology oversight

Board Governance

  • Committee assignments: Audit Committee Chair; Nominating & Corporate Governance Committee member; Technology & Information Security Committee member .
  • Independence: Board determined Markell is independent under Nasdaq rules; reviewed client relationships and found Brown University Health revenue to Huron <0.03% of Huron’s annual revenues, not impairing independence .
  • Attendance and engagement: Board met 8 times in 2024; overall Board/Committee attendance was 99% (Huron’s practice is all directors attend all committee meetings) .
  • Committee activity (2024): Audit (8 meetings); Compensation (7); Nominating & Corporate Governance (4); Technology & Information Security (5); Finance & Capital Allocation (6) .
  • Board leadership: Non-executive Chairman Hugh E. Sawyer chairs executive sessions; roles of Chair and CEO are separated .
CommitteeRole2024 Meetings
AuditChair8
Nominating & Corporate GovernanceMember4
Technology & Information SecurityMember5

Additional governance signals:

  • Board declassification underway; all directors elected annually starting 2024, with full declassification by 2026 .
  • Clawback policy expanded on Feb 14, 2025 to permit recovery/forfeiture for certain misconduct causing reputational or financial harm, in addition to Dodd-Frank requirements .
  • Hedging and pledging of company stock prohibited by Insider Trading Policy .
  • Say-on-pay support: 98% approval at 2024 annual meeting .

Fixed Compensation

Program structure for non-employee directors (effective Jan 1, 2024): $75,000 annual cash retainer; RSU grant with ~$170,000 grant-date fair value; committee chair/member retainers (Audit Chair $25,000; Audit membership $10,000; N&CG membership $7,500; Technology & Information Security membership $7,500); stock ownership requirement equal to 5x annual retainer ($375,000) .

Compensation Element2024 Amount ($)Notes
Cash fees (Board + committee)115,000Reflects $75,000 retainer + Audit Chair $25,000 + N&CG $7,500 + T&IS $7,500
Stock awards (RSUs)169,964Annual grant; vests ratably over 12 quarters; valued at closing price on grant date
Total284,964Sum of cash and stock awards
Ownership guideline5x annual cash retainer ($375,000)Applies to non-employee directors

Performance Compensation

Directors receive time-vested RSUs; no director performance metrics disclosed. RSUs vest ratably over 12 quarters, granted on annual meeting date, valued at closing price; no stock options disclosed for directors .

Equity ComponentGrant-Date Fair Value ($)VestingGrant Practice
RSUs (2024)169,964Ratably over 12 quartersGranted at annual meeting; priced at closing price on grant date

Other Directorships & Interlocks

  • Public company: Eastern Bank (audit chair; comp, risk, nom&gov member) .
  • Non-profit/academic: Boston College Board of Trustees (former Chairperson) .
  • Private company: CodaMetrix (audit committee member) .

No related-party transactions disclosed involving Eastern Bank or CodaMetrix in the proxy sections read; independence assessment focused on Brown University Health, Stanford University, and Boston Medical Center relationships .

Expertise & Qualifications

  • Financial expertise: CFO roles overseeing multibillion-dollar operations; audit partner background; designated audit committee financial expert .
  • Sector expertise: Healthcare and higher education leadership experience .
  • Governance/technology: Experience across governance, information systems, and risk management; service on multiple public and private boards .

Equity Ownership

ItemDetail
Beneficial ownership (shares)9,562
Shares outstanding17,921,212
Ownership as % of outstanding~0.053% (derived from 9,562 / 17,921,212)
Unvested RSUs vesting within 60 days of Record Date608
Additional unvested RSUs (beyond 60 days)2,621
Unvested RSUs at 12/31/2024 (snapshot)3,913
Ownership guideline complianceDirectors are in compliance with share ownership guidelines
Hedging/pledgingProhibited by company policy

Governance Assessment

  • Strengths: Independent director; Audit Committee Chair and audit financial expert; extensive CFO experience in complex healthcare systems; high board/committee attendance; robust clawback and anti-hedging/pledging policies; director ownership guidelines; board declassification in progress; strong shareholder support for compensation programs (98% say-on-pay) .
  • Potential conflicts: Employment at Brown University Health, a Huron client; board reviewed and quantified revenue exposure (<0.03% of Huron annual revenues) and affirmed independence, mitigating conflict risk .
  • Alignment: Director pay structured with a meaningful equity component and ownership requirements that promote alignment; RSUs’ multi-year vesting supports longer-term orientation .
  • Signals to investors: Audit leadership and financial expertise bolster board oversight quality; policy enhancements (clawback expansion) and board refresh/declassification are shareholder-friendly governance moves .